

## References

### S-163

1. *UpToDate*. 2017. [www.uptodate.com](http://www.uptodate.com).
2. InterQual® Level of Care Criteria. 2018. Acute Care Adult. McKesson Health Solutions,
3. Honold F, Camus M. Prophylactic mastectomy versus surveillance for the prevention of breast cancer in women's BRCA carriers. *Medwave*. 2018;18(4):e7161.
4. Jakub JW, Peled AW, Gray RJ, et al. Oncologic safety of prophylactic nipple-sparing mastectomy in a population With BRCA Mutations: A multi-institutional study. 2018;153(2):123-129.
5. Hegde J, Wang X, Attai D, Di Nome M, et al. Assessing the effect of lifetime contralateral breast cancer risk on the selection of contralateral prophylactic mastectomy for unilateral breast cancer. *Clin Breast Cancer*. 2018;18:E205-E218.
6. Nash R, Goodman M, Jemal A, et al. State Variation in the Receipt of a Contralateral Prophylactic Mastectomy Among Women Who Received a Diagnosis of Invasive Unilateral Early-Stage Breast Cancer in the United States, 2004-2012. *JAMA Surgery*. 2017;152(7):648-657.
7. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High- Risk Assessment: Breast and Ovarian. Version 3.2019.
8. Teoh V, Tasoulis M, and Gui G. Contralateral Prophylactic Mastectomy in women with unilateral breast cancer who are genetic carriers, have a strong family history or are just young at presentation. *Cancers*. 2020;12:140.
9. Bouchard-Fortier N, Baxter N, Sutradha R, Fernandes K, Camacho X, Graham P, and Quan M. Contralateral prophylactic mastectomy in young women with breast cancer: a population-based analysis of predictive factors and clinical impact. *Curr Oncol*. 2018;6:e562-e568.
10. The American Society of Clinical Oncology(ASCO), The American Society for Radiation Oncology (ASTRO), and Society of Surgical Oncology (SSO). *Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline*. *J Clin Oncol*. 2020 20;38(18):2080-2106.
11. McCarthy AM, Guan Z, Welch M, et al. Performance of breast cancer risk-assessment models in a large mammography cohort. *J Natl Cancer Inst*. 2020; 112(5): 489-497.
12. Tischkowitz M, Balmaña J, Foulkes WD, et al. Management of individuals with germline variants in PALB2: a clinical practice resource of the American

College of Medical Genetics and Genomics (ACMG). *Genet Med.* 2021;23(8):1416-1423.

13. Aslam A, Arshad Z, Ahmed A, et al. Bilateral risk-reducing mastectomy and reconstruction- a 12-year review of methodological trends and outcomes at a tertiary referral centre. *PLOS ONE.* 2023;18(4): e0281601. <https://doi.org/10.1371/journal.pone.0281601>.